TechnologySina News (新浪新闻)
First mRNA cancer vaccine clears Phase 3 trial, jointly developed by Moderna and Merck
全球首个mRNA癌症疫苗跑通三期临床
Moderna and Merck announced positive Phase 3 trial results for an individualized mRNA cancer vaccine. When combined with the immunotherapy Keytruda, the vaccine reduced the risk of recurrence or death in high-risk melanoma patients by 49% compared to Keytruda alone. The full data has not yet been published, but the companies plan to seek approval from the US FDA. The news drove a sharp rise in both companies' stock prices.
The view from inside
The piece, aggregated from a licensed mainland media outlet (红星新闻), reports the scientific achievement straightforwardly as an international breakthrough, without inserting a domestic policy angle.
Log in or create an account
Free. The read from inside China is the part we ask you to sign in for.